Please login to the form below

Not currently logged in
Email:
Password:

opioids

This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.

Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price

Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price

The bad reputation was attributed to, most notably, the ongoing opioid litigation against a number of pharma companies and ongoing scrutiny over medicine prices. ... According to Gallup: “The industry's rating likely will not recover until its role in

Latest news

More from news
Approximately 29 fully matching, plus 145 partially matching documents found.

Latest Intelligence

  • The transatlantic opioid crisis The transatlantic opioid crisis

    There’s some evidence to suggest similar transgressions in the UK with opioids. ... In another case, a single GP had ten patients addicted to synthetic opioids.

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    European operations, said the company is close to new registrations in Europe for opioid addiction products. ... be fully dedicated to helping patients, doctors and communities dealing with opioid addiction.’.

  • Trust: the ultimate elevator Trust: the ultimate elevator

    This is particularly apparent for the traditional ‘big pharma’ sector – shaken by scandals such as pricing, manipulative patent litigation and a rampant opioid epidemic.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    About 2.5m people have been diagnosed with opioid dependence in the US, and almost one million are receiving treatment. ... New to the opioid dependence treatment market this year is CAM2038, marketed by Camurus, a company headquartered in Lund, Sweden.

  • Pharma deals continue to slide Pharma deals continue to slide

    These companies have been running out of cash and have had to do deals to stay alive.  Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase

More from intelligence
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics